Influence of CYP2B6 516G > T and Long Term HAART on Population Pharmacokinetics of Efavirenz in Rwandan Adults on HIV and Tuberculosis Cotreatment

Emile Bienvenu^1*, Michael Ashton², Angela Äbelö²

¹School of Medicine, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
²Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden.

DOI: 10.4236/pp.2015.611055                

Abstract

Aim: To describe the pharmacokinetic parameters of efavirenz and estimate its clearance (CL/F) accounting simultaneously for drug-drug interactions and CYP2B6 genetic polymorphism. Methods: Genotyping of 516G > T single nucleotide polymorphism of CYP2B6 was performed using a PCR-based technology and plasma efavirenz concentrations were measured by high performance liquid chromatography on blood samples from 76 HIV adults co-infected with tuberculosis who had received an efavirenz-based regimen. Data were analyzed using population modeling with NONMEM. Results: The absorption rate constant and the apparent volume of distribution in the final model were 1.9 h^-1 and 580 L/70kg, respectively. The CL/F at baseline was 11.8 L/h/70kg, 8.8 L/h/70kg and 3.9 L/h/70kg for patients carrying the G/G, G/T and T/T genotypes of CYP2B6 516G > T, respectively, in patients who were administered tuberculosis (TB) treatment prior to HIV treatment (Group A); and 16.7 L/h/70kg, 10.6 L/h/70kg and 1.8 L/h/70kg for G/G, G/T and T/T genotype patients respectively, in patients with previous exposure to HIV treatment (Group B). The CL/F at baseline and steady state was always higher in Group B compared to Group A patients. Expectedly, carriers of CYP2B6 516G/G and T/T genotypes exhibited higher and lower CL/F, respectively. Conclusion: Our results indicated that the CL/F of efavirenz in the population studied was predictably different due to whether the patients were mono-treated for TB with HAART deferred or for HIV before initiation of TB therapy, and to CYP2B6 516G > T variant, implying that both CYP2B6 genetic polymorphisms and previous efavirenz-based HAART should be taken into account when adjusting efavirenz dose.

Keywords

Clearance, CYP2B6, Efavirenz, HIV, RBT, Tuberculosis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Hassan, M.N. (2013) Pathogenesis of HIV Infection. Infectious Disease Reports, 5, 1-6.
[2]	Hoffmann, C. and Rockstroh, J.K. (2013) HIV Book 2012/2013. http://hivbook.com/
[3]	Nieves, D.M., Plaud, M., Wojna, V., Skolasky, R. and Melendez, L. (2007) Characterization of Peripheral Blood Human Immunodeficiency Virus Isolates from Hispanic Women with Cognitive Impairment. Journal of NeuroVirology, 13, 315-327. http://dx.doi.org/10.1080/13550280701361508
[4]	World Health Organization (WHO) (2013) Global Tuberculosis Report 2013. WHO, Geneva.
[5]	Lawn, S.D. and Zumla, A. (2011) Tuberculosis. The Lancet, 378, 57-72. http://dx.doi.org/10.1016/S0140-6736(10)62173-3
[6]	Frieden, T.R., Sterling, T.R., Munsiff, S.S., Watt, C.J. and Dye, C. (2003) Tuberculosis. The Lancet, 362, 887-899. http://dx.doi.org/10.1016/S0140-6736(03)14333-4
[7]	Kunnath-Velayudhan, S. and Gennaro, M.L. (2011) Immunodiagnosis of Tuberculosis: A Dynamic View of Biomarker Discovery. Clinical Microbiology Reviews, 24, 792-805. http://dx.doi.org/10.1128/CMR.00014-11
[8]	Ottenhoff, T.H. and Kaufmann, S.H. (2012) Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? PLoS Pathog, 8, e1002607. http://dx.doi.org/10.1371/journal.ppat.1002607
[9]	Pozniak, A.L., Coyne, K.M., Miller, R.F., Lipman, M.C., Freedman, A.R., Ormerod L.P., Johnson, M.A., Collins, S. and Lucas, S.B. (2011) British HIV Association Guidelines for the Treatment of TB/HIV Coinfection 2011. HIV Medicine, 12, 517-524. http://dx.doi.org/10.1111/j.1468-1293.2011.00954.x
[10]	Avihingsanon, A., Hemachandra, A. and van de Lugt, J. (2009) Antiretroviral Therapy for HIV-Associated Tuberculosis. Asian Biomedicine, 3, 73-87.
[11]	World Health Organization (WHO) (2010) Treatment of Tuberculosis: Guidelines. Fourth Edition. http://www.who.int/tb/features_archive/new_treatment_guidelines_may2010/en/index.html
[12]	Bélanger, A.S., Caron, P., Harvey, M., Zimmerman, P.A., Mehlotra, R.K. and Guillemette, C. (2009) Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine. Drug Metabolism and Disposition, 37, 1793-1796. http://dx.doi.org/10.1124/dmd.109.027706
[13]	Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. and Desta, Z. (2010) Efavirenz Primary and Secondary Metabolism in Vitro and in Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation. Drug Metabolism and Disposition, 38, 1218-1229. http://dx.doi.org/10.1124/dmd.109.031393
[14]	Ward, B.A., Gorski, J.C., Jones, D.R., Hall, S.D., Flockhart, D.A. and Desta, Z. (2003) The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity. Journal of Pharmacology and Experimental Therapeutics, 306, 287-300. http://dx.doi.org/10.1124/jpet.103.049601
[15]	Kwara, A., Tashima, K.T., Dumond, J.B., Poethke, P., Kurpewski, J., Kashuba, A.D., Court, M.H. and Greenblatt, D.J. (2011) Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers. Antimicrobial Agents and Chemotherapy, 55, 3527-3533. http://dx.doi.org/10.1128/AAC.00980-10
[16]	Rodríguez-Nóvoa, S., Barreiro, P., Jiménez-Nácher, I. and Soriano, V. (2006) Overview of the Pharmacogenetics of HIV Therapy. Pharmacogenomics, 6, 234-245. http://dx.doi.org/10.1038/sj.tpj.6500374
[17]	Zhu, M., Kaul, S., Nandy, P., Grasela, D.M. and Pfister, M. (2009) Model-Based Approach to Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine. Antimicrobial Agents and Chemotherapy, 53, 2346-2353. http://dx.doi.org/10.1128/AAC.01120-08
[18]	Szalat, A., Gershkovich, P., Ben-Ari, A., Shaish, A., Liberman, Y., Boutboul, E., Gotkine, M., Hoffman, A., Harats, D., Leitersdorf, E. and Meiner, V. (2007) Rifampicin-Induced CYP3A4 Activation in CTX Patients Cannot Replace Chenodeoxycholic Acid Treatment. Biochimica et Biophysica Acta, 1771, 839-844. http://dx.doi.org/10.1016/j.bbalip.2007.04.012
[19]	Ngaimisi, E., Mugusi, S., Minzi, O.M., Sasi, P., Riedel, K.D., Suda, A., Ueda, N., Janabi, M., Mugusi, F., Haefeli, W.E., Burhenne, J. and Aklillu, E. (2010) Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients. Clinical Pharmacology & Therapeutics, 88, 676-684. http://dx.doi.org/10.1038/clpt.2010.172
[20]	Ngaimisi, E., Mugusi, S., Minzi, O.M., Sasi, P., Riedel, K.D., Suda, A., Ueda, N., Janabi, M., Mugusi, F., Haefeli, W.E., Burhenne, J. and Aklillu, E. (2011) Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients with or without Tuberculosis. Clinical Pharmacology & Therapeutics, 90, 406-413. http://dx.doi.org/10.1038/clpt.2011.129
[21]	Holzinger, E.R., Grady, B., Ritchie, M.D., Ribaudo, H.J., Acosta, E.P., Morse, G.D., Gulick, R.M., Robbins, G.K., Clifford, D.B., Daar, E.S., McLaren, P. and Haas, D.W. (2012) Genome-Wide Association Study of Plasma Efavirenz Pharmacokinetics in AIDS Clinical Trials Group Protocols Implicates Several CYP2B6 Variants. Pharmacogenetics and Genomics, 22, 858-867. http://dx.doi.org/10.1097/FPC.0b013e32835a450b
[22]	King, J. and Aberg, J.A. (2008) Clinical Impact of Patient Population Differences and Genomic Variation in Efavirenz Therapy. AIDS, 22, 1709-1717. http://dx.doi.org/10.1097/QAD.0b013e32830163ad
[23]	Sánchez, A., Cabrera, S., Santos, D., Valverde, M.P., Fuertes, A., Domínguez-Gil, A. and García, M.J. (2011) Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 55, 5314-5324. http://dx.doi.org/10.1128/AAC.00194-11
[24]	Bienvenu, E., Swart, M., Dandara, C., Ekman, A., Äbelö, A., Wonkam, A. and Ashton, M. (2013) Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations. Current Pharmacogenomics and Personalized Medicine, 11, 237-246. http://dx.doi.org/10.2174/18756921113119990006
[25]	Luetkemeyer, A.F., Rosenkranz, S.L., Lu, D., Marzan, F., Ive, P., Hogg, E., Swindells, S., Benson, C.A., Grinsztejn, B., Sanne, I.M., Havlir, D.V. and Aweeka, F. (2013) Relationship between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clinical Infectious Diseases, 57, 586-593. http://dx.doi.org/10.1093/cid/cit246
[26]	Kwara, A., Ramachandran, G. and Swaminathan, S. (2010) Dose Adjustment of the Non-Nucleoside Reverse Transcriptase Inhibitors during Concurrent Rifampicin-Containing Tuberculosis Therapy: One Size Does Not Fit All. Expert Opinion on Drug Metabolism & Toxicology, 6, 55-68. http://dx.doi.org/10.1517/17425250903393752
[27]	Rwandan Ministry of Health (2009) Guidelines for the Provision of Comprehensive Care to Persons Infected by HIV in Rwanda. MoH, Kigali, 38-41.
[28]	ter Heine, R., Scherpbier, H.J., Crommentuyn, K.M., Bekker, V., Beijnen, J.H., Kuijpers, T.W. and Huitema, A.D. (2008) A Pharmacokinetic and Pharmacogenetic Study of Efavirenz in Children: Dosing Guidelines Can Result in Subtherapeutic Concentrations. Antiviral Therapy, 13, 779-787.
[29]	Bienvenu, E., Hoffmann, K.J., Ashton, M. and Kayumba, P.C. (2013) A rapid and Selective HPLC-UV Method for the Quantitation of Efavirenz in Plasma from Patients on Concurrent HIV/AIDS and Tuberculosis Treatments. Biomedical Chromatography, 27, 1554-1559. http://dx.doi.org/10.1002/bmc.2959
[30]	Gengiah, T.N., Holford, N.H., Botha, J.H., Gray, A.L., Naidoo, K. and Abdool-Karim, S.S. (2012) The Influence of Tuberculosis Treatment on Efavirenz Clearance in Patients Co-Infected with HIV and Tuberculosis. The European Journal of Clinical Pharmacology, 68, 689-695. http://dx.doi.org/10.1007/s00228-011-1166-5
[31]	Mould, D.R. and Upton, R.N. (2012) Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development. CPT: Pharmacometrics & Systems Pharmacology, 1, 1-6. http://dx.doi.org/10.1038/psp.2012.4
[32]	Csajka, C., Marzolini, C., Fattinger, K., Décosterd, L.A., Fellay, J., Telenti, A., Biollaz, J. and Buclin, T. (2003) Population Pharmacokinetics and Effects of Efavirenz in Patients with Human Immunodeficiency Virus Infection. Clinical Pharmacology & Therapeutics, 73, 20-30. http://dx.doi.org/10.1067/mcp.2003.22
[33]	Kappelhoff, B.S., van Leth, F., MacGregor, T.R., Lange, J., Beijnen, J.H. and Huitema, A.D. (2005) Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2NN Study. Antiviral Therapy, 10, 145-155.
[34]	Cohen, K., Grant, A., Dandara, C., McIlleron, H., Pemba, L., Fielding, K., Charalombous, S., Churchyard, G., Smith, P. and Maartens, G. (2009) Effect of Rifampicin-Based Antitubercular Therapy and the Cytochrome P450 2B6 516G>T Polymorphism on Efavirenz Concentrations in Adults in South Africa. Antiviral Therapy, 14, 687-695.
[35]	Ramachandran, G., Hemanth, K.A.K., Rajasekaran, S., Kumar, P., Ramesh, K., Anitha, S., Narendran, G., Menon, P., Gomathi, C. and Swaminathan, S. (2009) CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India. Antimicrobial Agents and Chemotherapy, 53, 863-868. http://dx.doi.org/10.1128/AAC.00899-08
[36]	Li, T. and Chiang, J.Y. (2006) Rifampicin Induction of CYP3A4 Requires Pregnane X Receptor Cross Talk with Hepatocyte Nuclear Factor 4alpha and Coactivators, and Suppression of Small Heterodimer Partner Gene Expression. Drug Metabolism and Disposition, 34, 756-764. http://dx.doi.org/10.1124/dmd.105.007575
[37]	Bienvenu, E., Swart, M., Dandara, C. and Ashton, M. (2014) The Role of Genetic Polymorphisms in Cytochrome P450 and Effects of Tuberculosis Co-Treatment on the Predictive Value of CYP2B6 SNPs and on Efavirenz Plasma Levels in Adult HIV Patients. Antiviral Research, 102, 44-53. http://dx.doi.org/10.1016/j.antiviral.2013.11.011
[38]	To, K.W., Liu, S.T., Cheung, S.W., Chan, D.P., Chan, R.C. and Lee, S.S. (2009) Pharmacokinetics of Plasma Efavirenz and CYP2B6 Polymorphism in Southern Chinese. Therapeutic Drug Monitoring, 31, 527-530. http://dx.doi.org/10.1097/FTD.0b013e3181ad74a4
[39]	Gounden, V., van Niekerk, C., Snyman, T. and George, J.A. (2010) Presence of the CYP2B6 516G> T Polymorphism, Increased Plasma Efavirenz Concentrations and Early Neuropsychiatric Side Effects in South African HIV-Infected Patients. AIDS Research and Therapy, 7, 32. http://dx.doi.org/10.1186/1742-6405-7-32
[40]	Kwara, A., Lartey, M., Sagoe, K.W., Rzek, N.L. and Court, M.H. (2009) CYP2B6 (c.516G—>T) and CYP2A6 (*9B and/or *17) Polymorphisms Are Independent Predictors of Efavirenz Plasma Concentrations in HIV-Infected Patients. British Journal of Clinical Pharmacology, 67, 427-436. http://dx.doi.org/10.1111/j.1365-2125.2009.03368.x
[41]	Nyakutira, C., Röshammar, D., Chigutsa, E., Chonzi, P., Ashton, M., Nhachi, C. and Masimirembwa, C. (2008) High Prevalence of the CYP2B6 516G—> T(*6) Variant and Effect on the Population Pharmacokinetics of Efavirenz in HIV/AIDS Outpatients in Zimbabwe. European Journal of Clinical Pharmacology, 64, 357-365. http://dx.doi.org/10.1007/s00228-007-0412-3
[42]	Kwara, A., Lartey, M., Sagoe, K.W., Kenu, E. and Court, M.H. (2009) CYP2B6, CYP2A6 and UGT2B7 Genetic Polymorphisms Are Predictors of Efavirenz Mid-Dose Concentration in HIV-Infected Patients. AIDS, 23, 2101-2106. http://dx.doi.org/10.1097/QAD.0b013e3283319908
[43]	Kwara, A., Lartey, M., Sagoe, K.W., Xexemeku, F., Kenu, E., Oliver-Commey, J., Boima, V., Sagoe, A., Boamah, I., Greenblatt, D.J. and Court, M.H. (2008) Pharmacokinetics of Efavirenz When Co-Administered with Rifampin in TB/HIV Co-Infected Patients: Pharmacogenetic Effect of CYP2B6 Variation. Journal of Clinical Pharmacology, 48, 1032-1040. http://dx.doi.org/10.1177/0091270008321790